A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 362
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : LAMA
Long Form : long-acting muscarinic antagonist
No. Year Title Co-occurring Abbreviation
2022 A Pooled Analysis of Mortality in Patients with COPD Receiving Dual Bronchodilation with and without Additional Inhaled Corticosteroid. COPD, ICS, LABA, PS
2022 A randomized, crossover, placebo controlled, double-blind trial of the effects of tiotropium-olodaterol on neuromuscular performance during exercise in COPD. COPD, FEV1, FVC, IC
2022 An update on the currently available and emerging synthetic pharmacotherapy for uncontrolled asthma. ---
2022 Applying key learnings from the EMAX trial to clinical practice and future trial design in COPD. COPD, EMAX, ICS, LABA, SAL, UMEC
2022 Benefits of LAMA in patients with asthma-COPD overlap: A systematic review and meta-analysis. ACO, FEV1, FVC, PEF, RCTs
2022 Characteristics of New Users of Single- and Multiple-Inhaler Triple Therapy for COPD in Primary Care in England. COPD, FEV1, ICS, LABA, MRC
2022 Characteristics of Patients with Chronic Obstructive Pulmonary Disease Treated with Long-Acting Bronchodilators in a Real-World Setting in Singapore: A Single-Center Observational Study. COPD
2022 Comparing Clinical Outcomes of Tiotropium/Olodaterol, Umeclidinium/Vilanterol, and Indacaterol/Glycopyrronium Fixed-Dose Combination Therapy in Patients with Chronic Obstructive Pulmonary Disease in Taiwan: A Multicenter Cohort Study. COPD, LABA, PSM
2022 Disease Burden and Healthcare Utilization Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in England. COPD, ICS, LABA, MITT
10  2022 Effectiveness of Treatment With Dual Bronchodilation (LABA/LAMA) Compared With Combination Therapy (LABA/ICS) for Patients With COPD: A Population-Based Study. CI, ICS, LABA
11  2022 First Maintenance Therapy for Chronic Obstructive Pulmonary Disease: Retrospective Analyses of US and UK Healthcare Databases. COPD, ICS, LABA
12  2022 Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis. COPD, FEV1, ICS, LABA, NMA, RCTs, RMU, SGRQ, SLR
13  2022 Guidelines for the management of asthma in adults and adolescents: Position statement of the South African Thoracic Society - 2021 update. ICS, LABA, SABA, SATS
14  2022 Impact of switching from triple therapy to dual bronchodilation in COPD: the DACCORD 'real world' study. CAT, COPD, ICS, LABA
15  2022 Patient and Clinical Demographics of New Users to Single-Inhaler Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease. COPD, ICS, LABA, MITT
16  2022 Prescription Pathways from Initial Medication Use to Triple Therapy in Older COPD Patients: A Real-World Population Study. COPD, ICS, LABA
17  2022 Quantitative analysis of efficacy and safety of LABA/LAMA fixed-dose combinations in the treatment of stable COPD. AEs, CI, COPD, Emax, FDCs, LABA, SAEs, SGRQ, TDI
18  2022 Risk Assessment of Acute Myocardial Infarction and Stroke Associated with Long-Acting Muscarinic Antagonists, Alone or in Combination, versus Long-Acting beta2-Agonists. AMI, COPD, CPRD, IRRs, LABA/ICS, MACE
19  2022 The Impact of the Pay-for-Performance Program on the Outcome of COPD Patients in Taiwan After One Year. CAT, ICS, LABA
20  2022 The role of long-acting muscarinic antagonist/long-acting β agonist fixed-dose combination treatment for chronic obstructive pulmonary disease in China: a narrative review. COPD, FDCs, LABA, QoL
21  2022 Treatment Transitions in Chronic Obstructive Pulmonary Disease: Retrospective Analyses of US and UK Healthcare Databases. ICS, LABA
22  2022 Trends and Characteristics of Global Initiative for Chronic Obstructive Lung Disease Guidelines-Discordant Prescribing of Triple Therapy Among Patients with COPD. COPD, GOLD, ICS, LABA
23  2022 Update on Long-Acting Anticholinergics in Children and Adolescents With Difficult and Severe Asthma. ---
24  2022 Why small particle fixed dose triple therapy? An excursus from COPD pathology to pharmacological treatment evolution. BDP, CI, COPD, FF, ICS
25  2022 [SEVERE INFANTILE ASTHMA TREATED WITH LONG-ACTING MUSCARINIC ANTAGONIST: A CASE SERIES]. TIO
26  2021 A randomized controlled trial of long-acting muscarinic antagonist and long-acting beta2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease. COPD, FDCs
27  2021 Aclidinium bromide/formoterol fumarate as a treatment for COPD: an update. COPD, LABA
28  2021 Anti-interleukin-13 and anti-interleukin-4 agents versus placebo, anti-interleukin-5 or anti-immunoglobulin-E agents, for people with asthma. ED, ICS, LABA, OCS, s.c, Th2
29  2021 Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD. COPD, ICS, LABA, SITT
30  2021 Biomarkers to Predict Response to Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists in Adolescents and Adults with Mild Persistent Asthma. AUC, CI, FeNO, FEV1, ICS
31  2021 Budesonide/Glycopyrronium/Formoterol: A Review in COPD. COPD, HRQoL, ICS, LABA
32  2021 Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma: pooled analysis of phase 3 trials. CCV, CIs, F/S, GLY, MF/IND, RDs
33  2021 Chronic obstructive pulmonary disease: moving from symptom relief to mortality reduction. ACM, COPD, ICSs, LABA, LABDs
34  2021 Comparative Effectiveness of Initial LAMA versus LABA in COPD: Real-World Cohort Study. COPD, GOLD, HR, ICS, LABA
35  2021 Comparative efficacy of single-inhaler triple therapies for COPD: A protocol for systematic review and network meta-analysis. COPD, FDCs, GOLD, GRADE, ICS, LABA, NMA, RCT
36  2021 Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies. COPD, ED, ERS, FDC, HCRU, LABA, OLO, TIO, UMEC
37  2021 Comparison of Effectiveness Using Different Dual Bronchodilator Agents in Chronic Obstructive Pulmonary Disease Treatment. CAT, COPD, IND/GLY, LABA, TIO/OLO, UME/VIL
38  2021 Comparisons of Efficacy and Safety between Triple (Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist) Therapies in Chronic Obstructive Pulmonary Disease: Systematic Review and Bayesian Network Meta-Analysis. COPD, CrI, FP, ICS, LABA, OR, RCTs, SAL
39  2021 Dual versus monotherapy with bronchodilators in GOLD group B COPD patients according to baseline FEV1 level: a patient-level pooled analysis of phase-3 randomized clinical trials. COPD, FEV1, GOLD, LABA, SGRQ
40  2021 Dual versus single long-acting bronchodilator use could raise acute coronary syndrome risk by over 50%: A population-based nested case-control study. ACS, COPD, LABA
41  2021 Dual-combination maintenance inhaler preferences in asthma and chronic obstructive pulmonary disease: A patient-centered benefit-risk assessment. COPD, ICS, LABA, pMDI, PrCPs
42  2021 Effect of Adding Inhaled Corticosteroid to Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist Therapy Among Patients With Chronic Obstructive Pulmonary Disease. COPD, FVC, ICS, IOS
43  2021 Effectiveness and Safety of COPD Maintenance Therapy with Tiotropium/Olodaterol versus LABA/ICS in a US Claims Database. COPD, ICS, LABA
44  2021 Effects of treatment with long-acting muscarinic antagonists (LAMA) and long-acting beta-agonists (LABA) on lung function improvement in patients with bronchiectasis: an observational study. COPD, CT, FEV1, LABA, SD
45  2021 Efficacy and cardiovascular safety of LAMA in patients with COPD: a systematic review and meta-analysis. COPD, RR, WMD
46  2021 Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol Fumarate versus Other Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis. COPD, ICS, LABA, NMA
47  2021 Efficacy of preoperative inhaled LAMA/LABA combinations in patients with lung cancer and untreated COPD. COPD, FEV1, FVC, IQR, LABA, PPCs
48  2021 Evaluating a Cox marginal structural model to assess the comparative effectiveness of inhaled corticosteroids versus no inhaled corticosteroid treatment in chronic obstructive pulmonary disease. COPD, LABA, MSM
49  2021 Indacaterol/glycopyrronium/mometasone fixed dose combination for uncontrolled asthma. ---
50  2021 Indacaterol/Glycopyrronium/Mometasone: A Review in Asthma. ICS
51  2021 Inhaled indacaterol/glycopyrronium/mometasone furoate fixed-dose combination in moderate-to-severe asthma. ICS, LABA
52  2021 Inhaled therapies in COPD - all patients on fixed triple? COPD, ICS, LABA
53  2021 Long-Acting Bronchodilator Use in Chronic Obstructive Pulmonary Disease in Primary Care in New Zealand: A Retrospective Study of Treatment Patterns and Evolution Using the HealthStat Database. COPD, ICS, LABA, LABD
54  2021 Manifesto on inhaled triple therapy in asthma: an Interasma (Global Asthma Association - GAA) document. ICS, INES
55  2021 Personalising add-on treatment with inhaled corticosteroids in patients with chronic obstructive pulmonary disease: a benefit-harm modelling study. BEC, LABA
56  2021 Prognostic and functional impact of perioperative LAMA/LABA inhaled therapy in patients with lung cancer and chronic obstructive pulmonary disease. COPD, FEV1
57  2021 Real world effectiveness of benralizumab on respiratory function and asthma control. ACQ, BEC, EOT, LTRA, NP, OCS, SEA
58  2021 Real-World Treatment Patterns of Multiple-Inhaler Triple Therapy Among Patients with Chronic Obstructive Pulmonary Disease in UK General Practice. AECOPD, COPD, MITT
59  2021 RETRACTED: Comparison of efficacy and side effects of Fixed-dose combination of Aclidinium/Formoterol and Monotherapy of Aclidinium or Formoterol in COPD: A meta-analysis. ACL, COPD, FDC, FEV1, FOR, LABA, MD, SGRQ, TDI
60  2021 Safety evaluation of revefenacin at the approved dose in patients with chronic obstructive pulmonary disease: A meta-analysis. AEs, CIs, COPD, RCTs, RDs, RRs
61  2021 Single inhaler triple therapy (SITT) in asthma: Systematic review and practice implications. ICS, SITT
62  2021 The ALPACA study: (In)Appropriate LAMA prescribing in asthma: A cohort analysis. RR, SAE
63  2021 The Characteristics of Airflow Limitation and Future Exacerbations in Different GOLD Groups of COPD Patients. CAT, CCQ, COPD, GOLD, mMRC
64  2021 The Efficacy and Safety of Revefenacin for the Treatment of Chronic Obstructive Pulmonary Disease: A Systematic Review. AEs, COPD, FEV1, GRADE, RCTs, REV, SAEs
65  2021 Therapeutic Success of Tiotropium/Olodaterol, Measured Using the Clinical COPD Questionnaire (CCQ), in Routine Clinical Practice: A Multinational Non-Interventional Study. CCQ, COPD, GOLD, ICS, LABA
66  2021 Triple Inhaler versus Dual Bronchodilator Therapy in COPD: Real-World Effectiveness on Mortality. COPD, HR, ICS, LABA
67  2021 Triple versus LAMA/LABA combination therapy for Japanese patients with COPD: A systematic review and meta-analysis. ICS, LABA
68  2021 Triple versus LAMA/LABA combination therapy for patients with COPD: a systematic review and meta-analysis. ICS, LABA, QoL, RCTs
69  2021 [Chronic obstructive pulmonary disease: the right treatment for the right patient]. COPD, GOLD, ICS, LABA
70  2021 [The role of fixed dose combinations of inhaled cortikosteroids, long acting beta-2 agonists, and long acting muscarinic antagonists (ICS/LABA/LAMA) in the treatment of asthma]. ICS, LABA
71  2020 A comparison of tiotropium/olodaterol vs tiotropium alone in terms of treatment effect for chronic obstructive pulmonary disease: A meta-analysis. AEs, COPD, LABA, OLO, RCTs, TIO
72  2020 A Non-Interventional Study of Tiotropium/Olodaterol versus Any Triple Combination Therapy for Chronic Obstructive Pulmonary Disease: The EVELUT® Study Protocol. CAT, COPD, ICS, LABA, mMRC
73  2020 A Randomized, Noninferiority Trial Comparing ICS+ LABA with ICS+ LABA+ LAMA in Asthma-COPD Overlap (ACO) Treatment: The ACO Treatment with Optimal Medications (ATOMIC) Study. ACO, ATOMIC, ICSs
74  2020 Airway Deposition of Extrafine Inhaled Triple Therapy in Patients with COPD: A Model Approach Based on Functional Respiratory Imaging Computer Simulations. COPD, FEV1, HRCT, ICS, LABA, SITT
75  2020 Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO® and OTEMTO® Studies. CI, COPD, FEV1, GOLD, LABA, OR, OTEMTO, SGRQ, TDI
76  2020 Classification of Patients with COPD on LAMA Monotherapy Using the GOLD Criteria: Analysis of a Claims-Linked Patient Survey Study. CAT, COPD, GOLD, mMRC
77  2020 Comparing LAMA with LABA and LTRA as add-on therapies in primary care asthma management. ICS, LABAs, LTRAs
78  2020 COPD Maintenance Therapy with Tiotropium/Olodaterol Compared with Tiotropium: An Analysis in the Absence of Additional ICS Therapy. CI, FEV1, GOLD, ICS, LABA, SGRQ, TDI
79  2020 Critical Error Frequency and the Impact of Training with Inhalers Commonly used for Maintenance Treatment in Chronic Obstructive Pulmonary Disease. DPIs, ICS, LABA, ORs
80  2020 Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting beta2-agonist bronchodilators. ICS/LABA, LABA
81  2020 Dual- Versus Mono-Bronchodilator Therapy in Moderate to Severe COPD: A Meta-analysis. COPD, FEV1, LABA, MD, RCTs, SGRQ
82  2020 Effectiveness and Tolerability of LABA/LAMA Fixed-Dose Combinations Aclidinium/Formoterol, Glycopyrronium/Indacaterol and Umeclidinium/Vilanterol in the Treatment of COPD in Daily Practice - Results of the Non-Interventional DETECT Study. FDCs, FVC
83  2020 Effects of Tiotropium/Olodaterol on Activity-Related Breathlessness, Exercise Endurance and Physical Activity in Patients with COPD: Narrative Review with Meta-/Pooled Analyses. COPD, LABA
84  2020 Efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review. COPD, FDCs, RCTs
85  2020 Evaluating revefenacin as a therapeutic option for chronic obstructive pulmonary disease. COPD
86  2020 Extrafine Beclometasone Dipropionate/Formoterol Fumarate vs Double Bronchodilation Therapy in Patients with COPD: A Historical Real-World Non-Inferiority Study. BDP/FF, COPD, ICS, IRR, LABA, mMRC, OCS
87  2020 Frequency of Tiotropium Bromide Use and Clinical Features of Patients with Severe Asthma in a Real-Life Setting: Data from the Severe Asthma Network in Italy (SANI) Registry. SANI, TBR
88  2020 Functional respiratory imaging assessment of glycopyrrolate and formoterol fumarate metered dose inhalers formulated using co-suspension delivery technology in patients with COPD. FF MDI, FRI, GP MDI, LABA, siRaw
89  2020 Health and cost impact of stepping down asthma medication for UK patients, 2001-2017: A population-based observational study. ICSs, LABA, LTRA, NHS
90  2020 Impact of Comorbidities and Commonly Used Drugs on Mortality in COPD - Real-World Data from a Primary Care Setting. ASA, CI, COPD, HR, ICS, NAC
91  2020 Inhaled Corticosteroid Treatment in Chronic Obstructive Pulmonary Disease (COPD): Boon or Bane? COPD, GOLD, ICS, LABAs
92  2020 Inhaled Corticosteroid Treatment Regimens and Health Outcomes in a UK COPD Population Study. ICS, LABA
93  2020 Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD. FDCs, LABA
94  2020 LABA/LAMA fixed-dose combinations versus LAMA monotherapy in the prevention of COPD exacerbations: a systematic review and meta-analysis. CI, COPD, FDCs, LABA, RR
95  2020 Long-Term Safety and Efficacy of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD. AE, BFF, BGF MDI, GFF, ICS, LABA, TEAE
96  2020 Medication Discontinuation in Adults With COPD Discharged From the Hospital: A Population-Based Cohort Study. LABA-ICS
97  2020 New perspectives on the role of muscarinic antagonists in asthma therapy. ICSs
98  2020 One-year follow up of asthmatic patients newly initiated on treatment with medium- or high-dose inhaled corticosteroid-long-acting beta2-agonist in UK primary care settings. GINA, ICS-LABA, LTRA
99  2020 Patient Characteristics and Healthcare Resource Utilization Among Patients with COPD New to LAMA/LABA Fixed-Dose Combination Treatment in US-Based Real-World Practice. FDC, HCRU, LABA
100  2020 Patient-Reported Burden of Illness in a Prevalent COPD Population Treated with Long-Acting Muscarinic Antagonist Monotherapy: A Claims-Linked Patient Survey Study. CAT, COPD, EXACT-PRO, HCRU, mMRC, PROs